Marcus Chen
106 stories · Page 2 of 5
A Siberian Plague Lab Lost a Scientist, and Moscow Is Asking for the Trust It Burned at Sverdlovsk
Daria Shipilova, 28, studied plague in Irkutsk until a severe pneumonia killed her, and about 200 people were quarantined. The biology says stay calm. The history says make Moscow show its work.
Drugs & FDAThe FDA's Former Biologics Chief Says Public Health Can't See the Next Disaster Coming
Vinay Prasad ran the FDA's biologics center until this spring. His warning: the apparatus chases lettuce recalls and measles while a blood test for dozens of cancers heads toward Medicare with its central question unanswered.
InvestigationsThe MAHA Summit Charged Corporations Up to $300,000 for a Seat Beside the Officials Who Regulate Them
UnitedHealth got a panel. Grail, whose cancer test sat before the FDA, helped foot the bill. The regenerative ranchers and pesticide experts were nowhere on the program.
InvestigationsThe Fibroid Procedure That Spares the Uterus: Its Best Head-to-Head Evidence Was Paid For by the Device Maker
Radiofrequency ablation matched myomectomy on two-year symptom relief in a randomized trial. The device maker paid for that trial, and the durability question it cannot answer is the one that matters most.
Infectious DiseaseMonths After the FDA Recalled These Frozen Clams, No One Can Say Which Ecuadorian Waters Contaminated Them
Thirty-seven people across four states, thirty of them hospitalized, all linked to La Serranita black-shell clams imported frozen from Ecuador. The source waters are still under investigation.
InvestigationsThe Study Being Used to Close the Vaccine-Death Question Can't Rule Out Zero Excess Deaths in New Zealand
New Zealand's headline pandemic death study was co-authored by one of the country's most visible COVID modellers, and its four-year estimate runs from 1,134 fewer deaths than expected to 2,927 more. The modellers are calling it settled.
Drugs & FDAFour Years After Congress Dropped the Animal-Testing Requirement for New Drugs, the FDA Finally Updated Its Rulebook to Match
The FDA's direct final rule swaps 'animal studies' for 'nonclinical studies' across its regulations. It eliminates no animal testing, moves no evidentiary bar, and sets up no program to prove the alternatives it now invites actually work.
InvestigationsBrain on Fire: Ottawa's Vaccine-Injury Program Spent More on Its Contractor Than on the Injured
Fifty injured Canadians testified in Ottawa over four days, and Health Canada did not show. The compensation program has spent more on its contractor's overhead than on the people it was built to pay.
Infectious DiseaseCzech Trust in Government Fell to 19 Percent. Eight to Ten Weeks Later, the Death Rate Pulled Away from Austria's.
A populist government overstated its testing, cycled through health ministers, and governed by press conference. Czechs stopped believing it, and a new analysis ties that collapse of faith to a death rate that ran roughly twice the European average.
InvestigationsFifty Sworn Witnesses, 1,400 Who Applied, and Not One Official From Health Canada
A sitting MP put Canadians who say the COVID shots injured them under oath on Parliament Hill. Health Canada, which authorized the products and tracks their harms, sent no one.
InvestigationsThe Last Time Moderna's Stock Soared on Vaccine News, Insiders Sold $400 Million. It's Happening Again.
Moderna's stock has run up 137 percent in a month on a melanoma-vaccine trial that has not released its detailed data or reported overall survival. As retail chased the rally, the CEO sold $28.7 million in shares two weeks before the readout, and the rest of the C-suite cashed out after the stock tr
Drugs & FDATwenty Years, Four Botanical Drugs: The FDA Wants to Know What's Blocking the Rest
Four botanical drugs in two decades, under a framework built for single molecules. Now, inside RFK Jr.'s HHS, the agency that wrote those rules is asking what blocked the rest, and whether it means it.
Drugs & FDAA Fatal Brain Disease in Children Finally Has a Drug, and It Lists at $1.14 Million a Year
Ionis's zilganersen is the first therapy ever approved for Alexander disease, and it lists near $1.14 million a year. The same FDA approval handed Ionis a rare pediatric disease voucher, the transferable coupon that has resold for as much as $350 million.
Metabolic & WeightThe Heart Scan Sold to Everyone Barely Beats a Free Calculator, Except for the Patients Insurers Won't Cover
The scan barely moved the needle over a free calculator for most adults, but inside the muddy middle of risk, calcium separated a 1.9 percent ten-year danger from a 14.3 percent one.
Drugs & FDASickle Cell Finally Has a Cure. It Costs $2.2 Million and Has Reached 64 People.
Casgevy has kept Victoria Gray crisis-free for seven years. Getting it still means wiping out a patient's bone marrow with a chemo tied to infertility and malignancy warnings and paying about $3 million all in, and two years after approval only 64 people have been infused.
Infectious DiseaseThe FDA Is Fighting a Flesh-Eating Parasite We Eradicated in 1966 With a Flea Pill From 2000
Nitenpyram was approved in 2000 to kill fleas. It is now the emergency tool against a parasite the United States wiped out in 1966, after the sterile-fly barrier that kept the screwworm out was breached in 2023.
Nutrition & FoodSprouts Have Poisoned Thousands for a Quarter Century. The Wellness World Still Eats Them Raw.
Salmonella from Idaho broccoli sprouts has sickened 22 across four states, one more entry in a tally that logged 53 sprout outbreaks in two decades. The raw-is-best dogma is what keeps them coming.
InvestigationsThe Startup Selling 'Optimized' Babies Just Paid to Gene-Edit Human Embryos
Columbia scientists rewrote cholesterol and sickle-cell genes in human embryos, reaching 100 percent in embryos edited before their first division. The funder sells parents 'optimized' babies, and a germline edit like this could be inherited by every generation that follows.
Infectious DiseaseA 2014 Trial Warned That Correcting Vaccine Fears Backfires on the Hesitant. Public Health Corrected Harder.
A randomized trial found that correcting MMR-autism fears left the most hesitant parents less likely to vaccinate. A decade later, a panel of credentialed doctors in Sydney shows the trust cost of correcting harder anyway.
Drugs & FDAThe FDA Has Approved 4 Plant Drugs Since 2004. Now It's Asking the Public Why So Few Made It.
A request for public input is not reform. After two decades of a pathway that produced four approvals, the question is whether the agency wants plant medicine or just wants to talk about it.
Infectious DiseaseIn 1999, Fifteen Reports Suspended a Vaccine Within Weeks. The Spike Signal Has Waited Years for a Study.
Spike protein has turned up in the vessel-lining cells of vasculitic skin lesions 18 months after the shot, and adverse-event reports keep stacking up. The agencies that suspended a vaccine over fifteen reports in 1999 now call thousands a coincidence.
Drugs & FDAIonis Priced the First Alexander Disease Drug at $1.14 Million a Year, and Got a Federal Voucher It Can Resell for More Than $100 Million
Zilganersen is the first drug for Alexander disease, an antisense therapy designed to lower the toxic protein that drives a fatal brain disease. It also carries a $1.14 million annual price and a pediatric voucher Ionis can resell for more than $100 million.
InvestigationsAn AI Read 4.4 Million Mother-and-Baby Records and Says It Can Predict Illness. It Has Yet to Meet a Living Patient.
MoChiAgent forecasts maternal and infant disease from hospital records at a scale no clinician could read. A cautionary predecessor, Epic's sepsis tool, caught only a third of the cases it promised to catch.
InvestigationsPennsylvania Announced Two Measles Deaths Its County Coroner Never Recorded
Pennsylvania classified two Lancaster County fatalities as measles-associated, including a newborn the county coroner says he certified as dying from a ruptured spleen and blood loss. The CDC won't add either to the national count until the record shows measles caused or contributed to the deaths.